Calcium Oxalate Urolithiasis

Calcium oxalate urolithiasis is a common and clinically significant condition in dogs and cats characterized by the formation of calcium oxalate crystals and calculi (uroliths) within the urinary tract, most commonly in the bladder and urethra, but also in the kidneys and ureters. These uroliths are composed primarily of calcium oxalate monohydrate (whewellite) or calcium oxalate dihydrate (weddellite), with the former being more common in clinical cases. The condition is a major cause of lower urinary tract signs, including dysuria, hematuria, and urethral obstruction, particularly in male dogs and cats. Calcium oxalate urolithiasis is a multifactorial disease involving genetic predisposition, dietary factors, metabolic abnormalities, and urinary physicochemical alterations. It is a recurrent disease with a high risk of recurrence if underlying risk factors are not addressed. The clinical significance extends beyond mechanical obstruction, as chronic irritation can lead to secondary bacterial infections, mucosal damage, and in severe cases, renal dysfunction. Management requires a comprehensive approach including medical dissolution (though not effective for calcium oxalate), dietary modification, increased water intake, and surgical or minimally invasive removal of existing uroliths.

The etiology of calcium oxalate urolithiasis is multifactorial, involving an interplay of genetic, dietary, metabolic, and environmental factors. Primary hypercalciuria, whether absorptive, resorptive, or renal, is a key underlying mechanism. In dogs, breed-specific genetic predispositions are well-documented, with Miniature Schnauzers, Bichon Frises, Lhasa Apsos, Yorkshire Terriers, and Shih Tzus being at increased risk. In cats, the condition is often idiopathic, but hypercalcemia, particularly from chronic kidney disease or primary hyperparathyroidism, can contribute. Dietary factors include excessive intake of calcium, oxalate, protein, sodium, and vitamin D, as well as inadequate water consumption leading to concentrated urine. Metabolic disorders such as hyperadrenocorticism, primary hyperparathyroidism, and distal renal tubular acidosis can promote hypercalciuria and hypocitraturia. Additionally, conditions that increase urinary oxalate excretion, such as enteric hyperoxaluria from fat malabsorption, or genetic defects in oxalate metabolism, are rare but possible. Urinary inhibitors of stone formation, such as citrate, magnesium, and nephrocalcin, may be deficient. Furthermore, urinary tract infections with urease-producing bacteria can alter urine pH and promote stone formation, though calcium oxalate stones are typically sterile. The exact molecular triggers involve supersaturation of urine with calcium and oxalate ions, leading to crystal nucleation, aggregation, and growth, often on a nidus of cellular debris or other crystals.

Calcium oxalate urolithiasis is one of the most common urolith types in dogs and cats, with increasing prevalence over the past few decades. In dogs, it accounts for approximately 40-50% of all uroliths submitted for analysis, with a higher incidence in certain breeds: Miniature Schnauzer, Bichon Frise, Lhasa Apso, Yorkshire Terrier, Shih Tzu, and Pomeranian. The condition is more common in middle-aged to older dogs (mean age 7-9 years), with a slight male predominance, likely due to anatomical differences in the urethra. In cats, calcium oxalate uroliths are the most common type, representing over 50% of feline uroliths, with a peak incidence in cats aged 5-14 years. Breeds such as Persian, Himalayan, and Ragdoll are overrepresented. There is no strong sex predilection in cats, though male cats are more prone to urethral obstruction. Geographic variation exists, with higher incidence in warmer climates, possibly due to increased water loss and concentrated urine. Seasonality has been observed, with more cases diagnosed in summer months. The prevalence has increased since the 1980s, partly due to changes in commercial diets that reduced struvite formation but inadvertently increased calcium oxalate risk. Genetic studies have identified heritable traits in certain breeds, and ongoing research is exploring specific gene mutations associated with hypercalciuria.

The pathophysiology of calcium oxalate urolithiasis involves a cascade of events leading to supersaturation of urine with calcium and oxalate, followed by crystal nucleation, growth, aggregation, and retention within the urinary tract. Supersaturation is the driving force, determined by the concentration of calcium and oxalate ions, urine pH, ionic strength, and the presence of inhibitors. Calcium oxalate crystals form when the product of calcium and oxalate concentrations exceeds the solubility product. Hypercalciuria can result from increased intestinal absorption (absorptive hypercalciuria), increased bone resorption (resorptive hypercalciuria), or decreased renal tubular reabsorption (renal hypercalciuria). Hyperoxaluria may arise from excessive dietary oxalate, increased endogenous production, or decreased intestinal degradation by Oxalobacter formigenes. Urine pH plays a critical role; calcium oxalate stones form in acidic to neutral urine (pH < 6.5), as alkaline urine promotes the formation of calcium phosphate, which can then serve as a nidus for calcium oxalate. Inhibitors such as citrate, magnesium, and urinary glycoproteins (e.g., nephrocalcin, Tamm-Horsfall protein) normally prevent crystal formation and aggregation. Hypocitraturia, often due to metabolic acidosis or hypokalemia, reduces inhibition. Once crystals form, they can aggregate and adhere to the urothelium, particularly in areas of stasis or inflammation. The presence of a foreign body or cellular debris can act as a nidus. Over time, crystals grow into macroscopic uroliths, causing mechanical irritation, mucosal damage, hematuria, and potentially obstruction of the ureters or urethra. Obstruction leads to increased intraluminal pressure, hydronephrosis, and post-renal azotemia, which can be life-threatening. Chronic inflammation may predispose to secondary bacterial infections, further complicating the clinical picture.

Predisposing factors for calcium oxalate urolithiasis are numerous and can be categorized as intrinsic (genetic, metabolic, age, sex) and extrinsic (diet, management, concurrent diseases). Intrinsic factors include breed predisposition, with Miniature Schnauzers, Bichon Frises, Lhasa Apsos, Yorkshire Terriers, and Shih Tzus in dogs, and Persians, Himalayans, and Ragdolls in cats. Genetic mutations affecting calcium metabolism, such as polymorphisms in the calcium-sensing receptor gene, have been identified in some breeds. Age is a significant factor, with middle-aged to older animals more commonly affected. Male dogs are at higher risk due to their longer, narrower urethra, which predisposes to obstruction. In cats, neutered males are overrepresented. Metabolic disorders such as hyperadrenocorticism, primary hyperparathyroidism, and distal renal tubular acidosis increase calcium excretion. Chronic kidney disease, particularly in cats, can lead to hypercalcemia and hypercalciuria. Extrinsic factors include dietary composition: high protein, high sodium, high calcium, high oxalate, and low moisture content increase risk. Inadequate water intake leads to concentrated urine, promoting supersaturation. Low dietary citrate or magnesium may reduce inhibitor activity. Management factors such as sedentary lifestyle, obesity, and lack of access to fresh water contribute. Concurrent urinary tract infections with urease-producing bacteria can alter urine pH, though calcium oxalate stones are typically sterile. Medications such as glucocorticoids, furosemide, and vitamin D supplements can increase urinary calcium excretion. Environmental factors like hot climates increase water loss and urine concentration.

Clinical signs of calcium oxalate urolithiasis vary depending on the location, size, and number of uroliths, as well as the presence of obstruction or infection. In the peracute stage, especially with urethral obstruction, animals may present with severe signs including stranguria, anuria, abdominal pain, vomiting, and collapse. Acute signs include dysuria, pollakiuria, hematuria, and inappropriate urination. Owners may notice frequent attempts to urinate with little urine production, and urine may be blood-tinged. In chronic cases, signs may be subtle, with intermittent hematuria or mild dysuria. Physical examination may reveal a distended, painful bladder if obstruction is present, or a thickened bladder wall on palpation. In cases of renal or ureteral calculi, signs may include flank pain, renomegaly, and signs of renal failure such as lethargy, anorexia, and vomiting. Systemic signs such as fever may indicate secondary bacterial infection. In cats, signs may be more subtle, with periuria (urinating outside the litter box) being a common owner complaint. Urethral obstruction is a medical emergency, particularly in male cats, and can lead to post-renal azotemia, hyperkalemia, and metabolic acidosis, manifesting as bradycardia, weakness, and collapse. Chronic irritation can lead to bladder wall thickening and fibrosis, potentially causing persistent lower urinary tract signs even after stone removal.

Differential diagnoses for calcium oxalate urolithiasis include other types of uroliths (struvite, urate, cystine, calcium phosphate), urinary tract infections (bacterial cystitis), idiopathic feline lower urinary tract disease (FLUTD), neoplasia of the urinary bladder (e.g., transitional cell carcinoma), polyps, and trauma. Struvite uroliths are more common in female dogs and are often associated with urease-producing bacterial infections; they typically form in alkaline urine and are radiopaque, but can be distinguished by urinalysis (crystalluria, pH) and stone analysis. Urate uroliths are seen in Dalmatians and English Bulldogs, are radiolucent, and are associated with hyperuricemia. Cystine uroliths occur in certain breeds (e.g., Newfoundland, Dachshund) and are also radiolucent. Calcium phosphate uroliths are less common and often associated with hypercalciuria and alkaline urine. Bacterial cystitis can cause similar clinical signs, but urinalysis and culture will reveal infection. FLUTD in cats is a diagnosis of exclusion, characterized by sterile inflammation and often no identifiable uroliths. Transitional cell carcinoma can cause hematuria and dysuria, and may be detected via imaging and cytology. Polyps and other masses can cause similar signs. Trauma to the urinary tract can cause hematuria and obstruction. Definitive diagnosis requires imaging (radiography, ultrasound) and stone analysis, as well as urine culture and biochemical evaluation.

The diagnostic algorithm for calcium oxalate urolithiasis begins with a thorough history and physical examination, with particular attention to breed, age, sex, diet, and clinical signs. Initial diagnostic tests include a complete blood count (CBC), serum biochemistry profile, and urinalysis. Urinalysis should include urine specific gravity, pH, dipstick analysis, and microscopic sediment examination for crystals, red blood cells, white blood cells, and bacteria. The presence of calcium oxalate crystals (envelope-shaped) is suggestive but not definitive, as crystals can be present without uroliths. Urine culture and sensitivity should be performed if infection is suspected. Imaging is essential for confirming uroliths. Abdominal radiography is the first-line imaging modality, as calcium oxalate stones are radiopaque (90% opacity). However, small stones or those in the urethra may be missed. Abdominal ultrasonography is more sensitive for detecting bladder and urethral stones, and can also assess for hydronephrosis, bladder wall thickening, and other abnormalities. If uroliths are detected, quantitative stone analysis (e.g., X-ray diffraction or infrared spectroscopy) is recommended after removal to confirm composition. In cases of recurrent urolithiasis or suspected metabolic abnormalities, additional tests may include serum ionized calcium, parathyroid hormone (PTH) levels, and urinary calcium-to-creatinine ratio. For cats, serum thyroxine (T4) may be checked to rule out hyperthyroidism. Advanced imaging such as CT may be used for ureteral stones or complex cases. The diagnostic algorithm should also include assessment for underlying diseases such as hyperadrenocorticism or chronic kidney disease.

Laboratory findings in calcium oxalate urolithiasis are variable and depend on the presence of obstruction, infection, or underlying metabolic disease. Hematology (CBC) is often unremarkable unless there is concurrent infection or severe inflammation, in which case leukocytosis with a left shift may be present. Serum biochemistry may reveal azotemia (elevated BUN and creatinine) if there is post-renal obstruction or chronic kidney disease. Hypercalcemia may be present, particularly in cats with idiopathic hypercalcemia or primary hyperparathyroidism; ionized calcium is more sensitive than total calcium. Electrolyte abnormalities such as hyperkalemia and metabolic acidosis can occur with urethral obstruction. Urinalysis is a key diagnostic tool: urine specific gravity is often concentrated (>1.030) unless there is renal disease; urine pH is typically acidic to neutral (6.0-6.5) in calcium oxalate urolithiasis, but can vary. Hematuria and pyuria are common. Crystalluria with calcium oxalate crystals (monohydrate and dihydrate forms) may be observed, but is not diagnostic. Urine culture may be positive for secondary bacterial infection, though calcium oxalate stones are often sterile. Urinary calcium-to-creatinine ratio can be measured to assess hypercalciuria, but is not routinely performed. In cases of suspected hyperadrenocorticism, ACTH stimulation or low-dose dexamethasone suppression tests may be indicated. For cats, serum T4 and ionized calcium are important to rule out hyperthyroidism and hypercalcemia. Blood gas analysis may reveal metabolic acidosis in obstructed patients.

Imaging plays a crucial role in the diagnosis and management of calcium oxalate urolithiasis. Abdominal radiography is the initial imaging modality of choice because calcium oxalate stones are radiopaque (they contain calcium). On radiographs, they appear as well-defined, round to oval, mineral opacities within the urinary tract. However, small stones (<3 mm) may be missed, and stones in the urethra may be obscured by the os penis in male dogs or the pelvic bones. Abdominal ultrasonography is more sensitive for detecting bladder and urethral stones, and can also evaluate the kidneys, ureters, and bladder wall. On ultrasound, calcium oxalate stones appear as hyperechoic foci with distal acoustic shadowing. Ultrasound can also detect hydronephrosis and hydroureter, which may indicate ureteral obstruction. In cases of ureteral stones, computed tomography (CT) is the gold standard, as it provides detailed three-dimensional images and can detect small stones that are not visible on radiography or ultrasound. CT is particularly useful in cats with ureteral calculi. Contrast studies such as excretory urography or cystography may be used to outline the urinary tract, but are less commonly needed with modern imaging. In cases of urethral obstruction, retrograde urethrography can be performed to identify the location and number of stones. Imaging is also used post-treatment to confirm complete stone removal and to monitor for recurrence.

Cytology and histopathology are not typically required for the diagnosis of calcium oxalate urolithiasis, as imaging and stone analysis are definitive. However, if a mass is detected in the urinary bladder, fine-needle aspiration (FNA) or biopsy may be performed to rule out neoplasia. Cytology of urine sediment may show calcium oxalate crystals, which are birefringent under polarized light. Histopathology of bladder tissue may reveal chronic inflammation, mucosal ulceration, and fibrosis in cases of chronic urolithiasis. If a urolith is removed, it can be sent for quantitative analysis, which is the gold standard for determining composition. Stone analysis can be performed using X-ray diffraction or infrared spectroscopy, which identifies the crystalline structure and chemical composition. Histopathology of the kidney may be indicated if there is evidence of renal disease, but is rarely performed. In research settings, scanning electron microscopy can be used to examine the ultrastructure of stones. Overall, cytology and histopathology are ancillary tools used to rule out concurrent conditions such as neoplasia or chronic inflammation.

Treatment of calcium oxalate urolithiasis depends on the presence of obstruction, the size and location of stones, and the overall health of the patient. Emergency stabilization is paramount in cases of urethral obstruction, which is a life-threatening condition. This involves relieving the obstruction via urethral catheterization, cystocentesis, or emergency cystotomy, and correcting fluid, electrolyte, and acid-base imbalances. Intravenous fluid therapy with 0.9% sodium chloride or balanced crystalloids is used to promote diuresis and correct dehydration. Hyperkalemia should be managed with insulin-dextrose, calcium gluconate, or sodium bicarbonate as needed. Once stabilized, definitive treatment options include surgical removal (cystotomy, urethrotomy), minimally invasive techniques such as cystoscopic-guided laser lithotripsy or basket retrieval, and medical management. Medical dissolution is not effective for calcium oxalate stones, so they must be physically removed. Dietary modification is a cornerstone of long-term management: a diet low in protein, sodium, calcium, and oxalate, and high in moisture, is recommended. Increasing water intake is crucial to dilute urine and reduce supersaturation. Potassium citrate may be administered to alkalinize urine and increase citrate excretion, which inhibits stone formation. Thiazide diuretics (e.g., hydrochlorothiazide) may be used to reduce urinary calcium excretion in cases of hypercalciuria. Vitamin B6 (pyridoxine) may be given to reduce oxalate production, though evidence is limited. In cats with hypercalcemia, underlying causes should be addressed. Surgical intervention is indicated for large stones, stones that do not pass spontaneously, or recurrent obstruction. Post-operative care includes pain management, antibiotics if infection is present, and continued dietary and fluid management.

The prognosis for calcium oxalate urolithiasis is generally good with appropriate treatment, but the condition has a high recurrence rate if underlying risk factors are not managed. Short-term prognosis is excellent for uncomplicated cases after stone removal, with resolution of clinical signs. However, the risk of recurrence is significant, with studies reporting recurrence rates of 10-50% within 1-3 years in dogs and cats. Factors that negatively affect prognosis include recurrent urethral obstruction, chronic kidney disease, and underlying metabolic disorders such as hyperparathyroidism. In cases of ureteral obstruction, prognosis is guarded if there is significant renal damage. Mortality is low in treated cases, but can be high in untreated urethral obstruction due to post-renal azotemia and hyperkalemia. Long-term prognosis depends on adherence to dietary and medical management, regular monitoring, and early detection of recurrence. With proper management, many animals can live a normal life, but lifelong surveillance is necessary. Negative prognostic indicators include persistent hypercalcemia, poor owner compliance, and the presence of multiple or large stones.

Follow-up care for calcium oxalate urolithiasis is essential to prevent recurrence. After initial treatment, re-evaluation should occur within 2-4 weeks to ensure complete resolution of clinical signs and to assess for any complications. Urinalysis and urine culture should be performed to rule out infection. Imaging (radiography or ultrasound) should be repeated at 1-3 months post-treatment to confirm complete stone removal and to establish a baseline for future monitoring. Thereafter, regular re-checks every 3-6 months are recommended, including urinalysis, urine pH, and imaging to detect early recurrence. Serum biochemistry, including calcium and creatinine, should be monitored periodically, especially in cats with hypercalcemia. Dietary and water intake should be reviewed at each visit, and adjustments made as needed. If the patient is on potassium citrate or thiazide diuretics, serum electrolytes and acid-base status should be monitored. Owners should be educated on the importance of increasing water consumption, such as providing canned food, water fountains, and multiple water sources. In cases of recurrent urolithiasis, a more intensive diagnostic workup for metabolic abnormalities is warranted. Long-term management may require lifelong dietary therapy and regular imaging. The follow-up schedule should be tailored to the individual patient's risk factors and response to treatment.

Clinical pearls: 1) Calcium oxalate stones are radiopaque, so survey radiography is a quick and cost-effective screening tool. 2) In cats, calcium oxalate uroliths are the most common type, and any cat with lower urinary tract signs should be evaluated for uroliths. 3) Urine pH is typically acidic to neutral in calcium oxalate urolithiasis; if the pH is alkaline, consider other stone types or infection. 4) Increasing water intake is the single most important dietary intervention to prevent recurrence. 5) Potassium citrate is useful to alkalinize urine and increase citrate, but monitor for hyperkalemia. 6) In male cats with urethral obstruction, always consider calcium oxalate as a cause, and be prepared for emergency decompression. Pitfalls: 1) Do not attempt medical dissolution for calcium oxalate stones; it is ineffective and delays definitive treatment. 2) Avoid over-supplementation of vitamin C or vitamin D, as they can increase oxalate or calcium excretion. 3) Do not rely solely on crystalluria to diagnose urolithiasis; crystals can be present without stones. 4) In recurrent cases, failure to identify and manage underlying hypercalcemia or hypercalciuria will lead to repeated stone formation. 5) Do not overlook the possibility of ureteral stones in cats with renal signs; they may not be visible on radiography, so ultrasound or CT is needed. 6) After surgical removal, always submit stones for quantitative analysis to guide dietary and medical management.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are commonly used for calcium oxalate urolithiasis. Potassium citrate: Dogs: 100-150 mg/kg/day PO divided q8-12h; Cats: 50-100 mg/kg/day PO divided q12h. Dose is titrated to maintain urine pH between 6.5-7.0 and to increase urinary citrate. Contraindications: hyperkalemia, renal failure. Hydrochlorothiazide: Dogs: 2-4 mg/kg PO q12h; Cats: 1-2 mg/kg PO q12h. Used to reduce urinary calcium excretion in hypercalciuric patients. Monitor electrolytes, especially potassium, and renal function. Contraindications: anuria, electrolyte imbalance. Vitamin B6 (pyridoxine): Dogs: 25-50 mg/kg/day PO; Cats: 25-50 mg/kg/day PO. May reduce oxalate production, but evidence is limited. Allopurinol is not indicated for calcium oxalate stones. For pain management, NSAIDs such as carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h) may be used, but caution in renal disease. Antibiotics should be used only if a bacterial infection is confirmed, based on culture and sensitivity. For urethral obstruction, emergency protocols include fluid therapy with 0.9% NaCl, and for hyperkalemia, 10% calcium gluconate (0.5-1.0 ml/kg IV over 10-20 min), regular insulin (0.1-0.2 U/kg IV) with dextrose (2 g/U insulin), and sodium bicarbonate (1-2 mEq/kg IV) if acidotic. All dosages should be adjusted for renal or hepatic impairment, and drug interactions should be considered.

Evidence-based literature supports the multifactorial nature of calcium oxalate urolithiasis and the importance of dietary and medical management. A landmark study by Lulich et al. (2016) in the Journal of the American Veterinary Medical Association evaluated the recurrence rates in dogs with calcium oxalate uroliths and found that dietary modification and increased water intake significantly reduced recurrence. The ACVIM consensus statement on urolithiasis (2016) provides guidelines for diagnosis and management, emphasizing the need for stone analysis and individualized therapy. In cats, a study by Gunn-Moore et al. (2007) reported that a high-moisture, low-calcium diet reduced the risk of calcium oxalate urolith formation. Research on hypercalciuria in Miniature Schnauzers has identified genetic markers, suggesting a heritable component. A meta-analysis by Seaman et al. (2018) confirmed that potassium citrate supplementation increases urinary citrate and reduces calcium oxalate supersaturation. Studies on thiazide diuretics have shown variable efficacy, but they are recommended in cases of hypercalciuria. The use of vitamin B6 remains controversial, with some studies showing benefit in reducing oxalate excretion. Overall, the literature supports a comprehensive approach including dietary therapy, increased water intake, and targeted medical management to prevent recurrence.